Active, Not Recruiting
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumor, +60 more
- Locations
-
- Highlands Oncology Group Springdale, Arkansas, United States
- UC Irvine Cancer Center Orange, California, United States
- UC Davis Cancer Center Sacramento, California, United States
- UCSF San Francisco, California, United States